Eli Silver
Pediatric Allergy/Immunology · Cleveland, OHNPI 1740377449
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,734 of the $4,446 with a category attached, or 84.0%. It is spread thinly across 19 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations.
Across 224 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$876
- Sanofi$619
- GSK$614
- Kaleo, Inc.$346
- Chiesi USA, Inc.$300
- Amgen$288
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$67515%
- Food & beverage$3,73484%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $876 |
| Sanofi | 28 | $619 |
| GSK | 60 | $614 |
| Kaleo, Inc. | 24 | $346 |
| Chiesi USA, Inc. | 1 | $300 |
| Amgen | 14 | $288 |
| Genentech USA, Inc. | 15 | $240 |
| Novartis | 12 | $224 |
| Aimmune Therapeutics, Inc. | 4 | $212 |
| Shire North American Group Inc | 1 | $200 |
| Regeneron Healthcare Solutions, Inc. | 8 | $152 |
| Pfizer | 9 | $147 |
| Ionis Pharmaceuticals, Inc. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Phadia US Inc. | 2 | $33 |
| Galderma Laboratories, L.p. | 2 | $29 |
| Blueprint Medicines Corporation | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,446 in reported general payments places this provider in the 75th percentile of 42 pediatric allergy/immunology providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 18 | $49,208 |
| TezspireTezepelumab-Ekko | 11 | $44,026 |
| Montelukast Sodium | 13 | $131 |
| Amoxicillin | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire | $876 | $44,02611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 42 pediatric allergy/immunology providers in Ohio.
Other pediatric allergy/immunology in Cleveland
- Melvin BergerCleveland$288K
- Brian SchroerCleveland$48K
- Jaclyn BjelacCleveland$3K
- Bridget WilsonCleveland$1K
- John McDonnellCleveland$993
- Kara McNamaraCleveland$670
- Kobkul ChotikanatisCleveland$255
- Julie SterbankCleveland$163
- Alton MeltonCleveland$17
- Leigh KernsCleveland$17
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.